Dautzenberg Frank M, Hauger Richard L
Therapeutic Applications, Axovan, Innovation Center, Gewerbestrasse 16, 4123, Allschwil, Switzerland.
Trends Pharmacol Sci. 2002 Feb;23(2):71-7. doi: 10.1016/s0165-6147(02)01946-6.
Abnormal signaling at corticotropin-releasing factor CRF1 and CRF2 receptors might contribute to the pathophysiology of stress-related disorders such as anxiety, depression and eating disorders, in addition to cardiac and inflammatory disorders. Recently, molecular characterization of CRF1 and CRF2 receptors and the cloning of novel ligands--urocortin, stresscopin-related peptide/urocortin II, and stresscopin/urocortin III--have revealed a far-reaching physiological importance for the family of CRF peptides. Although the physiological roles of the CRF2 receptor remain to be defined, the preclinical and clinical development of specific small-molecule antagonists of the CRF1 receptor opens new avenues for the treatment of psychiatric and neurological disorders.
促肾上腺皮质激素释放因子CRF1和CRF2受体的异常信号传导可能不仅会导致心脏和炎症性疾病，还会引发与压力相关的疾病，如焦虑症、抑郁症和饮食失调症的病理生理过程。最近，CRF1和CRF2受体的分子特征以及新型配体——尿皮质素、应激肽相关肽/尿皮质素II和应激肽/尿皮质素III的克隆，揭示了CRF肽家族具有深远的生理重要性。尽管CRF2受体的生理作用仍有待确定，但CRF1受体特异性小分子拮抗剂的临床前和临床开发为精神和神经疾病的治疗开辟了新途径。
